• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PAA
Click for more information
0.00% 21.0¢

PHARMAUST LIMITED - News & Media

Market Cap $93.45M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare

PharmAust Limited is a clinical-stage biotechnology company developing therapeutics for... PharmAust Limited is a clinical-stage biotechnology company developing therapeutics for human and animal health applications. The Company’s segments include Corporate and Research. The Company is focused on repurposing monepantel (MPL) for human neurodegenerative diseases. The Company's lead candidate, Monepantel (MPL), is a potent and safe inhibitor of the mTOR pathway, that plays a central role in cell growth and proliferation of cancer cells and in degenerating neurons. The Company is also developing MPL as a treatment for motor neuron disease (MND/ALS), a rare, incurable disease. It is focused on starting Phase II/III clinical study of MPL. It has also completed a Phase II oncology clinical study of MPL in humans and pilot studies in canine cancer. It is also preparing a pivotal monepantel field trial in dogs with B-Cell Lymphoma to enable product registration in the United States.More

Articles & Videos

PharmAust reappoints MD and resets its sights on MND battle

Biotechnical company PharmAust has reappointed Dr Michael Thurn as Managing Director and and Dr Nicky Wallis as Chief Scientific Officer.

31 May 2024 09:28 (AEST)

PharmAust CEO's sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of its CEO, Dr. Michael Thurn.

23 Apr 2024 12:08 (AEST)

PharmAust teams up with Berry Consultants for phase 2/3 MND study

PharmAust (ASX:PAA) is collaborating with renowned clinical study design expert, Berry Consultants, to design and analyse its planned phase 2/3 study for monepantel in patients with MND and ALS.

16 Jan 2024 13:34 (AEDT)

Pharmaust completes Phase One Monepantel study and files for Orphan Drug Designation

Pharmaust (ASX:PAA) has announced that all patients have completed its phase one MEND study using monepantel (MPL) to test its functions on Motor Neuron Disease (MND).

01 Dec 2023 11:32 (AEDT)

PharmAust completes dosing in phase one MND trial

Pharmaust (ASX:PAA) has finished dosing all patients in cohort four of its phase one MEND study using monepantel (MPL) to treat Motor Neurone Disease.

13 Oct 2023 10:50 (AEDT)

PharmAust (ASX:PAA) welcomes Dr Michael Thurn as new CEO

PharmAust (ASX:PAA) has appointed Dr Michael Thurn as its newest Chief Executive Officer, starting from September 1.

28 Aug 2023 15:09 (AEST)

PharmAust's (ASX:PAA) phase one trial indicates MPL's potential to slow MND progression

Pharmaust (ASX:PAA) has reported that its phase one trial using the lead drug, MPL, for MND/ALS has successfully slowed disease progression in 11 out of 12 patients.

22 Aug 2023 11:41 (AEST)

PharmAust's (ASX:PAA) subsidiary Epichem enters voluntary liquidation

PharmAust (ASX:PAA) has appointed joint and several liquidators from Grant Thornton Australia, to administer the creditor's voluntary winding-up proceedings for PAA's subsidiary, Epichem.

01 Aug 2023 13:39 (AEST)

PharmAust's (ASX:PAA) Beagle patient surpasses one year on MPL

PharmAust’s (ASX:PAA) patient, Louie the Beagle, has surpassed one year of treatment with the company’s Monepantel (MPL) drug.

06 Jul 2023 13:42 (AEST)

PharmAust (ASX:PAA) reports positive preliminary data in MND/ALS trial

PharmAust (ASX:PAA) has released preliminary data from its phase 1/2 trial assessing its lead drug candidate MPL in MND/ALS0.

04 Jul 2023 16:25 (AEST)



(20min delay)
Last
21.0¢ 		Change
0.000(0.00%) 		Mkt cap ! $93.45M
Open High Low Value Volume
21.0¢ 21.5¢ 20.5¢ $106.7K 516.1K

Buyers (Bids)

No. Vol. Price($)
2 24033 20.5¢
 

Sellers (Offers)

Price($) Vol. No.
21.0¢ 55077 2
View Market Depth
Last trade - 15.22pm 22/07/2024 (20 minute delay) ?
Last
21.0¢ 		  Change
0.000 ( 0.00 %)
Open High Low Volume
21.0¢ 21.0¢ 20.5¢ 342599
Last updated 15.22pm 22/07/2024 ?
PAA (ASX) Chart

Top Stories

Pure Hydrogen inks MOU for 5 hydrogen buses in Saigon – days after Twiggy's FFI reeled back in

Pure Hydrogen has confirmed it's executed an MOU with a Vietnam-based entity to develop hydrogen-fuelled buses.
HBF to throw 10% vote behind NDC BidCo's buyout of Pacific Smiles Group Pacific Smiles Group has confirmed 10% shareholder HBF – the private health insurer – will vote in favour of PSQ's buyout by NDC BidCo.
Biden's exit bakes in a Kamala Harris ballot while markets expect Trump to win. How could equities fare this week? Joe Biden, current US President, has agreed to drop out of the 2024 Presidential election following internal disagreement.
High-grade copper results provide some relief to 29Metals after earlier mine shutdown 29Metals Ltd has reported positive results from a 3-hole program of drilling in Queensland, finding up to 4.8% copper.
Large fault structure and uranium anomalies picked up by Infini at Newfoundland play Infini Resources Ltd has revealed the presence of a large fault structure connected to anomalies at its Portland Creek uranium project.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.